LY-307,452: Difference between revisions

Latest revision as of 19:20, 22 March 2025

A chemical compound studied for its pharmacological properties

LY-307,452 is a chemical compound that has been studied for its potential pharmacological effects. It is of interest in the field of neuroscience and pharmacology due to its action on specific receptor systems in the central nervous system.

Chemical Structure[edit]

LY-307,452 is a synthetic compound with a complex chemical structure. It belongs to a class of compounds known as heterocyclic compounds, which are characterized by rings containing at least one atom other than carbon. The specific structure of LY-307,452 allows it to interact with certain neurotransmitter receptors, influencing their activity.

Pharmacological Action[edit]

LY-307,452 has been studied primarily for its action as a receptor antagonist. It is known to bind to specific serotonin receptors, particularly the 5-HT2A receptor, which plays a role in various neurological and psychiatric processes. By blocking these receptors, LY-307,452 can modulate the effects of serotonin in the brain, potentially influencing mood, perception, and cognition.

Research and Development[edit]

Research on LY-307,452 has been conducted to explore its potential therapeutic applications. Studies have investigated its effects in models of psychiatric disorders, such as schizophrenia and depression, where dysregulation of serotonin systems is implicated. The compound's ability to alter receptor activity makes it a candidate for further investigation in the development of new psychotropic drugs.

Potential Applications[edit]

The potential applications of LY-307,452 are primarily in the treatment of mental health disorders. By modulating serotonin receptor activity, it may offer benefits in conditions where traditional treatments are ineffective or cause undesirable side effects. However, more research is needed to fully understand its efficacy and safety profile.

Related pages[edit]

@@ Line 1: / Line 1: @@
-[[File:LY-307,452.svg|LY-307,452|thumb]]
+{{Short description|A chemical compound studied for its pharmacological properties}}
-'''LY-307,452''' is a drug used in neuroscience research, which was among the first compounds found that acts as a selective antagonist for the group II metabotropic glutamate receptors ([[Metabotropic glutamate receptor|mGluR<sub>2/3</sub>]]),<ref name="pmid8632404">{{cite journal |author=Wermuth CG, Mann A, Schoenfelder A, Wright RA, Johnson BG, Burnett JP, Mayne NG, Schoepp DD |title=(2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)-pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase |journal=Journal of Medicinal Chemistry |volume=39 |issue=4 |pages=814–6 |date=February 1996 |pmid=8632404 |doi=10.1021/jm9508144 |url=}}</ref> and was useful in early studies of this receptor family,<ref name="pmid10516668">{{cite journal |author=Li XC, Beart PM, Monn JA, Jones NM, Widdop RE |title=Type I and II metabotropic glutamate receptor agonists and antagonists evoke cardiovascular effects after intrathecal administration in conscious rats |journal=[[British Journal of Pharmacology]] |volume=128 |issue=3 |pages=823–9 |date=October 1999 |pmid=10516668 |pmc=1571690 |doi=10.1038/sj.bjp.0702850 |url=}}</ref><ref name="pmid11698530">{{cite journal |author=Sung KW, Choi S, Lovinger DM |title=Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses |journal=Journal of Neurophysiology |volume=86 |issue=5 |pages=2405–12 |date=November 2001 |pmid=11698530 |doi= |url=}}</ref> although it has largely been replaced by newer drugs such as [[LY-341,495]].
+'''LY-307,452''' is a chemical compound that has been studied for its potential pharmacological effects. It is of interest in the field of [[neuroscience]] and [[pharmacology]] due to its action on specific [[receptor]] systems in the [[central nervous system]].
-== References ==
-<references/>
+==Chemical Structure==
-{{Glutamate_receptor_ligands}}
+LY-307,452 is a synthetic compound with a complex chemical structure. It belongs to a class of compounds known as [[heterocyclic compounds]], which are characterized by rings containing at least one atom other than carbon. The specific structure of LY-307,452 allows it to interact with certain [[neurotransmitter]] receptors, influencing their activity.
-[[Category:Eli Lilly and Company]]
-{{pharmacology-stub}}
+==Pharmacological Action==
+LY-307,452 has been studied primarily for its action as a [[receptor antagonist]]. It is known to bind to specific [[serotonin]] receptors, particularly the [[5-HT2A receptor]], which plays a role in various [[neurological]] and [[psychiatric]] processes. By blocking these receptors, LY-307,452 can modulate the effects of serotonin in the brain, potentially influencing mood, perception, and cognition.
+==Research and Development==
+Research on LY-307,452 has been conducted to explore its potential therapeutic applications. Studies have investigated its effects in models of [[psychiatric disorders]], such as [[schizophrenia]] and [[depression]], where dysregulation of serotonin systems is implicated. The compound's ability to alter receptor activity makes it a candidate for further investigation in the development of new [[psychotropic drugs]].
+==Potential Applications==
+The potential applications of LY-307,452 are primarily in the treatment of [[mental health]] disorders. By modulating serotonin receptor activity, it may offer benefits in conditions where traditional treatments are ineffective or cause undesirable side effects. However, more research is needed to fully understand its efficacy and safety profile.
+==Related pages==
+* [[Serotonin receptor]]
+* [[Neurotransmitter]]
+* [[Pharmacology]]
+* [[Psychiatric disorder]]
+[[Category:Chemical compounds]]
+[[Category:Pharmacology]]
+[[Category:Neuroscience]]